U.S. FDA approves Travere Therapeutics kidney disorder drug
Send a link to a friend
[February 18, 2023]
By Sriparna Roy, Nandhini Srinivasan and Khushi Mandowara
(Reuters) -Travere Therapeutics said on Friday the U.S. health regulator
has granted accelerated approval to its drug to treat a type of chronic
kidney disease, IgAN, in adults with a high risk of advancing to kidney
failure.
Shares of the drugmaker were up 2.8% at $18.32 after market
The drug, with the brand name Filspari, comes with a boxed warning for
inflammation in liver and birth defects. Patients will need to be tested
for liver toxicity before starting the drug.
During the treatment, patients would be profiled for toxicity data on a
monthly frequency for the first 12 months, and then once in every three
months.
The approval pits Filspari against Calliditas Therapeutics' Tarpeyo,
which was greenlit by the U.S. Food and Drug Administration in December
2021.
![](http://archives.lincolndailynews.com/2023/Feb/18/images/ads/current/humanesociety_sda022411.png)
Filspari will be priced at $9,900 per month, making it cheaper than
Tarpeyo's cost of $14,160 per month or $170,000 a year. At least three
analysts expected the list price of Travere's drug to be between $70,000
and $100,000 a year.
Jefferies analyst Maury Raycroft estimates that for the year, Travere
could make about $35 million in 2023 from sales of the kidney drug. It
is expected to have peak sales of $745 million in the United States.
[to top of second column]
|
![](../images/021823PIX/health43.jpg)
Signage is seen outside of the Food and
Drug Administration (FDA) headquarters in White Oak, Maryland, U.S.,
August 29, 2020. REUTERS/Andrew Kelly
![](http://archives.lincolndailynews.com/2023/Feb/18/images/ads/current/graue_lda_preowned_NEWENCORE_021323.jpg) Travere expects to launch the drug
by end of the month through its specialty distributors and specialty
pharmacies in the United States.
IgA nephropathy (IgAN), also called Berger's disease, occurs when
immunoglobulin A antibodies, proteins made by the immune system to
protect the body, build up in the kidneys, damaging tissues and
leaking blood and protein into urine.
The tissue damage affects the filtering ability of the kidneys, and
eventually progresses to end-stage kidney failure. Analysts estimate
that about 150,000 patients suffer from this condition in the U.S.
(Reporting by Sriparna Roy, Khushi Mandowara and Nandhini Srinivasan
in Bengaluru; Editing by Krishna Chandra Eluri)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
![](http://archives.lincolndailynews.com/2023/Feb/18/images/ads/current/charrons_bch_2022.png) |